AI Article Synopsis

  • - The study investigates a new test (indirect immunofluorescence cell-based assay, CBA) for detecting anti-MAG IgM antibodies, which are linked to an autoimmune disorder affecting peripheral nerves.
  • - Researchers tested this new method on samples from 95 patients with confirmed anti-MAG neuropathy and 55 patients with other neuropathy types, showing a very high sensitivity of 98.9% and a perfect specificity of 100% compared to the traditional testing method (ELISA).
  • - The CBA offers a faster and easier way to detect these antibodies and could potentially improve the monitoring of anti-MAG levels over time, although further large studies are recommended for more robust findings.

Article Abstract

Peripheral neuropathy with antibodies to myelin-associated glycoprotein (MAG) is an autoimmune demyelinating disorder of the peripheral nervous system caused by pathogenic IgM recognizing the human natural killer-1 glycoepitope expressed on MAG. This study aimed to analyze the performance of a new indirect immunofluorescence cell-based assay (CBA, EUROIMMUN) for the detection of anti-MAG IgM. Antibody reactivity was determined in sera from 95 patients with clinical and neurophysiological evidence of anti-MAG-associated neuropathy and in control samples from 55 patients with other forms of peripheral neuropathy. Compared to the results of the gold standard method (ELISA, Bühlmann) and using samples at a dilution of 1:100, the CBA had a sensitivity of 98.9% and a specificity of 100% (PPV 100%, NPV 98.2%). In conclusion, the CBA allows the detection of antibodies to MAG using an easy and standardized technique, and it presents a sensitive and specific alternative to the more time-consuming ELISA. Larger studies are needed to address anti-MAG titer monitoring in parallel with clinical activity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758835PMC
http://dx.doi.org/10.3389/fneur.2023.1289810DOI Listing

Publication Analysis

Top Keywords

myelin-associated glycoprotein
8
peripheral neuropathy
8
novel cell-based
4
cell-based immunofluorescence
4
immunofluorescence assay
4
assay detection
4
detection autoantibodies
4
autoantibodies myelin-associated
4
glycoprotein peripheral
4
neuropathy antibodies
4

Similar Publications

Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders.

Neurol Neuroimmunol Neuroinflamm

March 2025

Neuroimmunology Laboratory and Neuroimmunology Research Section, IRCCS Mondino Foundation, Pavia, Italy.

Background And Objectives: Antibodies to proteolipid protein-1 (PLP1-IgG), a major central myelin protein also expressed in the peripheral nervous system (PNS) as the isoform DM20, have been previously identified mostly in patients with multiple sclerosis (MS), with unclear clinical implications. However, most studies relied on nonconformational immunoassays and included few patients with non-MS CNS autoimmune demyelinating disorders (ADDs). We aimed to investigate conformational PLP1-IgG in the whole ADD spectrum.

View Article and Find Full Text PDF

Objectives: To report myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) epidemiology in two American regions using 2023 diagnostic criteria.

Patients And Methods: We compared age- and sex-adjusted incidence and prevalence of MOGAD per 2023 diagnostic criteria in Olmsted County (Minnesota [USA]) and Martinique (Caribbean [FR]) (01/01/2003-12/31/2018, prevalence day) using Poisson regression. Archived sera in 68-85% were available for MOG-IgG testing by live cell-based assay at Mayo Clinic.

View Article and Find Full Text PDF

Evaluation of the predictive value of CSF-restricted oligoclonal bands on residual disability and risk of relapse in adult patients with MOGAD: MOGADOC study.

Mult Scler

January 2025

Service de Neurologie, Sclérose en Plaques, Pathologie de la Myéline et Neuro-Inflammation, Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.

Background: The clinical course of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is variable. However, robust markers of poor outcome and/or relapse risk are still missing.

Objective: To evaluate the frequency of cerebrospinal fluid-restricted oligoclonal bands (CSF-OCB) in a national cohort of adult MOGAD patients and to assess their prognostic value for the risk of relapse and severity.

View Article and Find Full Text PDF

The Polygenic Nature of Multiple Sclerosis: Genetic Variants, Immunological Modulation, and Environmental Connections.

Endocr Metab Immune Disord Drug Targets

December 2024

Institute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev St., Block 23, Sofia1113, Bulgaria.

Multiple Sclerosis (MS), a debilitating inflammatory disorder of the central nervous system characterized by demyelination, is significantly influenced by polygenic variations. Although the precise cause of MS remains unclear, it is believed to arise from a complex interplay of genetic and environmental factors. Recent investigations have focused on the polygenic nature of genetic alterations linked to MS risk.

View Article and Find Full Text PDF

The Role of Artificial Intelligence in Predicting Optic Neuritis Subtypes From Ocular Fundus Photographs.

J Neuroophthalmol

December 2024

Division of Ophthalmology (EB-S, AS, AA-A, AS-B, DW, SS, FC), Department of Surgery, University of Calgary, Calgary, Canada; Department of Biomedical Engineering (CN), University of Calgary, Calgary, Canada; Departments of Neurology (LBDL) and Ophthalmology (LBDL), University of Michigan, Ann Arbor, Michigan; and Department of Clinical Neurosciences (SS, FC), University of Calgary, Calgary, Canada.

Background: Optic neuritis (ON) is a complex clinical syndrome that has diverse etiologies and treatments based on its subtypes. Notably, ON associated with multiple sclerosis (MS ON) has a good prognosis for recovery irrespective of treatment, whereas ON associated with other conditions including neuromyelitis optica spectrum disorders or myelin oligodendrocyte glycoprotein antibody-associated disease is often associated with less favorable outcomes. Delay in treatment of these non-MS ON subtypes can lead to irreversible vision loss.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!